|
|
| General |
| Study Status |
Delayed |
Application Number /
Requirement Number |
P200002 / PAS001 |
| Date Original Protocol Accepted |
04/28/2021
|
| Date Current Protocol Accepted |
10/07/2025
|
| Study Name |
CONVERGE Post-Approval Study
|
| Device Name |
EPi-Sense Guided Coagulation System
|
| Clinical Trial Number(s) |
NCT01984346
|
| General Study Protocol Parameters |
| Study Design |
Prospective Cohort Study
|
| Data Source |
New Data Collection
|
| Comparison Group |
No Control
|
| Analysis Type |
Descriptive
|
| Study Population |
Transit. Adolescent B (as adults) : 18-21 yrs,
Adult: >21
|
| Detailed Study Protocol Parameters |
| Study Objectives |
The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense and Epi-Sense ST Guided Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.
The study is a prospective single arm study with safety and effectiveness compared to performance goals which are based upon published literature.
|
| Study Population |
Patients diagnosed with long-standing persistent AF defined in accordance with the 2017 HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement.
Long-standing Persistent: Continuous AF of greater than 12-months duration.
|
| Sample Size |
52 Subjects were enrolled at 23 sites including sites in US, UK and EU
|
| Key Study Endpoints |
The primary effectiveness endpoint is defined as freedom from AF/AT/AFL absent class I and III AADs except for a previously failed or intolerant class I or III AAD with no increase in dosage following the 3-month blanking period through the 12-months post procedure follow-up visit
The Primary Safety Endpoint is the severe adverse event rate through 12-months post-procedure.
The primary safety endpoint for the study includes major adverse events (MAEs):
The incidence of MAEs through 30-days post Hybrid Convergent procedure
The incidence of MAEs related to Hybrid Convergent procedure
The incidence of MAEs related to Hybrid Convergent devices
Additional endpoints: Clinically significant pericardial effusion;
Device and procedure related serious adverse events through 12-months post-procedure;
Change in AF symptoms from baseline to 12-, 18-, 24-, and 36-months post-procedure;
Freedom from AF/AT/AFL >30 seconds duration absent class I and III AADs except for a previously failed or intolerant class I or III AAD with no increase in dosage following the 3-month blanking period through the 12-months post procedure follow-up visit. Evaluated based on the first 24 hours of the 7-days Holter monitoring and symptom-driven event monitoring;
Freedom from any AF/AFL/AT >30 seconds duration without a Class I/III AAD prescribed for AF following the 3-month blanking period through 12- 18-, 24- and 36- months post-procedure;
Freedom from any AF/AFL/AT >30 seconds duration with or without an AAD prescribed for AF following the 3-month blanking period through 12-, 18-, 24- and 36- months post -procedure;
Residual AF burden / reduction in overall AF burden at 12-, 18-, 24- and 36-months post procedure when compared to baseline; and
Change in AF-specific Quality of Life (QoL) score(s) at 12-, 18-, 24- and 36- months post-index procedure when compared to baseline score.
|
| Follow-up Visits and Length of Follow-up |
All treated subjects will be followed for a total of 36-months.
|
| Interim or Final Data Summary |
| Interim Results |
Safety Results
47 events have been reported in 20 subjects, where 22 events were serious. 5 events have been adjudicated to meet the primary endpoint thus far.
Effectiveness Results
Insufficient information available for any effectiveness conclusions
|
| Actual Number of Patients Enrolled |
36
|
| Actual Number of Sites Enrolled |
25
|
| Patient Follow-up Rate |
12-months: 9/36
24-months: 5/36
36-months: 0/36
|
